SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer gains on transferring Upjohn business to Mylan Pharmaceuticals for Rs 180.48 crore

02 Aug 2022 Evaluate

Pfizer is currently trading at Rs. 4250.00, up by 30.20 points or 0.72% from its previous closing of Rs. 4219.80 on the BSE.

The scrip opened at Rs. 4240.00 and has touched a high and low of Rs. 4250.00 and Rs. 4220.10 respectively. So far 300 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6164.80 on 08-Sep-2021 and a 52 week low of Rs. 4056.00 on 29-Jun-2022.

Last one week high and low of the scrip stood at Rs. 4250.00 and Rs. 4120.45 respectively. The current market cap of the company is Rs. 19355.87 crore.

The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 17.38% and 18.70% respectively.

Pfizer has transferred its certain primarily off-patent branded and generic established medicines business (Upjohn Business) comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities to Mylan Pharmaceuticals, effective August 1, 2022. Accordingly, the Company has received the purchase consideration of Rs 180.48 crore from Mylan Pharmaceuticals. Earlier, the company had entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer Share Price

4864.70 -34.75 (-0.71%)
16-Apr-2026 14:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1682.90
Dr. Reddys Lab 1223.90
Cipla 1231.45
Zydus Lifesciences 937.40
Lupin 2309.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×